Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
Enochian BioSciences announced its participation in the H.C. Wainwright Global Life Sciences Conference on September 13, 2021. CEO Dr. Mark Dybul will present the company's advancements in gene-modified cellular and immune therapies targeting infectious diseases and cancer, including platforms for HIV, Hepatitis B, influenza, and coronavirus. The presentation will be accessible on-demand starting at 7:00 AM Eastern on the same day via the Enochian BioSciences website.
- None.
- None.
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
Dr. Mark Dybul, CEO will provide an overview of the company’s progress, including its innovative HIV, Hepatitis B, influenza and coronavirus infections, and Oncology platforms. The presentation will be available on-demand for conference attendees beginning at 7:00 am Eastern on Monday September 13, 2021, and will be available on the Enochian BioSciences website under the Investors/Media section in Events and Presentations.
More information on the conference may be found at H.C. Wainwright’s conference website.
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit Enochianbio.com
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
FAQ
What is the date of Enochian BioSciences' presentation at the H.C. Wainwright conference?
Who is presenting for Enochian BioSciences at the conference?
What topics will be covered in Enochian BioSciences' presentation?
Where can I view the presentation from Enochian BioSciences?
What time will Enochian BioSciences' presentation be available on September 13, 2021?
